407 related articles for article (PubMed ID: 30654773)
21. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome.
Ford AC; Moayyedi P
Aliment Pharmacol Ther; 2010 Jul; 32(2):144-58. PubMed ID: 20412064
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Peppermint oil in diarrhea predominant IBS - a double blind randomized placebo - controlled study.
Alam MS; Roy PK; Miah AR; Mollick SH; Khan MR; Mahmud MC; Khatun S
Mymensingh Med J; 2013 Jan; 22(1):27-30. PubMed ID: 23416804
[TBL] [Abstract][Full Text] [Related]
23. Western herbal medicines in the treatment of irritable bowel syndrome: A systematic review and meta-analysis.
Hawrelak JA; Wohlmuth H; Pattinson M; Myers SP; Goldenberg JZ; Harnett J; Cooley K; Van De Venter C; Reid R; Whitten DL
Complement Ther Med; 2020 Jan; 48():102233. PubMed ID: 31987249
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis.
Ford AC; Brandt LJ; Young C; Chey WD; Foxx-Orenstein AE; Moayyedi P
Am J Gastroenterol; 2009 Jul; 104(7):1831-43; quiz 1844. PubMed ID: 19471254
[TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of probiotics in patients with irritable bowel syndrome: Evidence based on 35 randomized controlled trials.
Niu HL; Xiao JY
Int J Surg; 2020 Mar; 75():116-127. PubMed ID: 32014597
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis.
Sun JR; Kong CF; Qu XK; Deng C; Lou YN; Jia LQ
Saudi J Gastroenterol; 2020; 26(2):66-77. PubMed ID: 31898645
[TBL] [Abstract][Full Text] [Related]
27. Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: Systematic review and meta-analysis.
Barberio B; Savarino EV; Black CJ; Ford AC
Neurogastroenterol Motil; 2022 Jun; 34(6):e14279. PubMed ID: 34672052
[TBL] [Abstract][Full Text] [Related]
28. A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers.
Weerts ZZRM; Keszthelyi D; Vork L; Aendekerk NCP; Frijlink HW; Brouwers JRBJ; Neef C; Jonkers DMAE; Masclee AAM
Adv Ther; 2018 Nov; 35(11):1965-1978. PubMed ID: 30284674
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials.
Wu J; Lv L; Wang C
Front Cell Infect Microbiol; 2022; 12():827395. PubMed ID: 35295757
[TBL] [Abstract][Full Text] [Related]
30. Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials.
Li J; Zhu W; Liu W; Wu Y; Wu B
Medicine (Baltimore); 2016 Jan; 95(4):e2534. PubMed ID: 26825893
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis.
Ford AC; Quigley EM; Lacy BE; Lembo AJ; Saito YA; Schiller LR; Soffer EE; Spiegel BM; Moayyedi P
Am J Gastroenterol; 2014 Oct; 109(10):1547-61; quiz 1546, 1562. PubMed ID: 25070051
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis.
Xu D; Chen VL; Steiner CA; Berinstein JA; Eswaran S; Waljee AK; Higgins PDR; Owyang C
Am J Gastroenterol; 2019 Jul; 114(7):1043-1050. PubMed ID: 30908299
[TBL] [Abstract][Full Text] [Related]
33. The efficacy of Shugan Jianpi Zhixie therapy for diarrhea-predominant irritable bowel syndrome: a meta-analysis of randomized, double-blind, placebo-controlled trials.
Xiao Y; Liu Y; Huang S; Sun X; Tang Y; Cheng J; Wang T; Li F; Kuang Y; Luo R; Zhao X
PLoS One; 2015; 10(4):e0122397. PubMed ID: 25853241
[TBL] [Abstract][Full Text] [Related]
34. Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis.
Ford AC; Lacy BE; Harris LA; Quigley EMM; Moayyedi P
Am J Gastroenterol; 2019 Jan; 114(1):21-39. PubMed ID: 30177784
[TBL] [Abstract][Full Text] [Related]
35. Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome.
Ianiro G; Eusebi LH; Black CJ; Gasbarrini A; Cammarota G; Ford AC
Aliment Pharmacol Ther; 2019 Aug; 50(3):240-248. PubMed ID: 31136009
[TBL] [Abstract][Full Text] [Related]
36. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis.
Pittler MH; Ernst E
Am J Gastroenterol; 1998 Jul; 93(7):1131-5. PubMed ID: 9672344
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis.
Ford AC; Talley NJ; Schoenfeld PS; Quigley EM; Moayyedi P
Gut; 2009 Mar; 58(3):367-78. PubMed ID: 19001059
[TBL] [Abstract][Full Text] [Related]
38. Eluxadoline Versus Antispasmodics in the Treatment of Irritable Bowel Syndrome: An Adjusted Indirect Treatment Comparison Meta-analysis.
Qin D; Tao QF; Huang SL; Chen M; Zheng H
Front Pharmacol; 2022; 13():757969. PubMed ID: 35281934
[No Abstract] [Full Text] [Related]
39. Review article: the physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders.
Chumpitazi BP; Kearns GL; Shulman RJ
Aliment Pharmacol Ther; 2018 Mar; 47(6):738-752. PubMed ID: 29372567
[TBL] [Abstract][Full Text] [Related]
40. Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial.
Ballou S; Kaptchuk TJ; Hirsch W; Nee J; Iturrino J; Hall KT; Kelley JM; Cheng V; Kirsch I; Jacobson E; Conboy L; Lembo A; Davis RB
Trials; 2017 May; 18(1):234. PubMed ID: 28545508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
